ASO Author Reflections: Reflections on the Role of the Systemic Immune-Inflammation Index in Prognostic Assessment in HER2-Positive Metastatic Breast Cancer

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 10

PMID 39656393

Authors

Jian Pang

Nianhua Ding

Xuan Liu

Xiongbin He

Wei Zhou

Haiqing Xie

Jianqi Feng

Yan Li

Yingjian He

Shouman Wang

Zhi Xiao

Affiliations

Soon will be listed here.

Citing Articles

ASO Author Reflections: Reflections on the Role of the Systemic Immune-Inflammation Index in Prognostic Assessment in HER2-Positive Metastatic Breast Cancer.

Pang J, Ding N, Liu X, He X, Zhou W, Xie H Ann Surg Oncol. 2024; 32(3):2110-2111.

PMID: 39656393 DOI: 10.1245/s10434-024-16664-0.

References

Baselga J, Cortes J, Kim S, Im S, Hegg R, Im Y . Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2011; 366(2):109-19. PMC: 5705202. DOI: 10.1056/NEJMoa1113216. View

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

Pang J, Ding N, Liu X, He X, Zhou W, Xie H . Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials. Ann Surg Oncol. 2024; 32(2):750-759. DOI: 10.1245/s10434-024-16454-8. View

Pang J, Ding N, Liu X, He X, Zhou W, Xie H . ASO Author Reflections: Reflections on the Role of the Systemic Immune-Inflammation Index in Prognostic Assessment in HER2-Positive Metastatic Breast Cancer. Ann Surg Oncol. 2024; 32(3):2110-2111. DOI: 10.1245/s10434-024-16664-0. View